iBio(US:IBIO)2025-11-12 21:05Revenue - Revenue for the three months ended September 30, 2025, was $0.1 million, compared to no revenue for the same period in 2024[8] Expenses - Research and Development expenses increased to $3.6 million for the three months ended September 30, 2025, from $1.3 million in 2024, representing an increase of approximately 176.9%[8] - General and Administrative expenses decreased to approximately $2.5 million for the three months ended September 30, 2025, from $2.8 million in 2024, a decrease of about 10.7%[8] - Total operating expenses for the three months ended September 30, 2025, were $6.05 million, compared to $4.11 million in 2024, an increase of approximately 47.2%[11] Financial Position - iBio held cash, cash equivalents, and investments in debt securities of $49.6 million as of September 30, 2025, sufficient to support operations into the fourth quarter of fiscal year 2027[8] - iBio's total assets increased to $64.16 million as of September 30, 2025, from $23.19 million as of June 30, 2025[13] Net Loss - iBio reported a net loss of $5.72 million for the three months ended September 30, 2025, compared to a net loss of $3.99 million for the same period in 2024[11] Capital Raising - iBio closed a $50 million underwritten public offering with the potential for an additional $50 million in gross proceeds upon full exercise of the common warrants, totaling up to $100 million before deducting underwriting discounts and commissions[3] Compliance - iBio regained compliance with Nasdaq Listing Rule 5550(a)(2) on November 4, 2025[3] Product Development - The predicted human half-life of IBIO-610 is up to 100 days, allowing for dosing as infrequent as twice per year[3]